Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 3, 2014, Pages 200-208

  O'riordan, Thomas G ^a   Donn, Karl H ^b   Hodsman, Peter ^c   Ansede, John H ^b   Newcomb, Terry ^a   Lewis, Sandra A ^a   Flitter, William D ^a   White, Vicki Shigekane ^a   Johnson, M Ross ^b   Montgomery, A Bruce ^d   Warnock, David G ^e   Boucher, Richard C ^f  

^a GILEAD SCIENCES INC   (United States)

^b Parion Sciences   (United States)

^c Nucleus Network Ltd   (Australia)

^d Cardeas Pharma   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Amiloride; Cystic fibrosis; Epithelial sodium channels; Potassium sparing diuretic; Renal potassium excretion; Urine electrolytes

Indexed keywords

ELECTROLYTE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; GS 9411; PLACEBO; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; BACKACHE; COHORT ANALYSIS; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ELECTROLYTE URINE LEVEL; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HUMAN; HYPERKALEMIA; HYPERSALIVATION; LETHARGY; MALE; MORNING DOSAGE; MUCOCILIARY CLEARANCE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; OBSERVATIONAL STUDY; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SODIUM ABSORPTION; SODIUM URINE LEVEL; TOOTH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; WHEEZING; ACUTE DISEASE; AUSTRALIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; INHALATIONAL DRUG ADMINISTRATION; RISK ASSESSMENT; URINE; YOUNG ADULT;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADULT; AUSTRALIA; BIOMARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EPITHELIAL SODIUM CHANNEL BLOCKERS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYPERKALEMIA; MALE; POTASSIUM; RISK ASSESSMENT; YOUNG ADULT;

EID: 84901721726     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1037     Document Type: Article

References (28)

1. Berdiev BK, Qadri YJ, and Benos DJ: Assessment of the CFTR and ENaC association. Mol Biosyst. 2009;5:123-127
2. Knowles MR, and Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109:571-577. (Pubitemid 34204834)
3. Van der Schans CP: Bronchial mucus transport. Respir Care. 2007;52:1150-1158
4. Boucher RC: Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261:5-16
5. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, and Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354:241-250. (Pubitemid 43113029)
6. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, and Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group: A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354:229-240. (Pubitemid 43113028)
7. Jaques A, Daviskas E, Turton JA, McKay K, Cooper P, Stirling RG, Robertson CF, Bye PT, Lesouéf PN, Shadbolt B, Anderson SD, and Charlton B: Inhaled mannitol improves lung function in cystic fibrosis. Chest. 2008;133:1388-1396
8. Bilton D, Robinson P, Cooper P, Gallagher CG, Kolbe J, Fox H, Jaques A, and Charlton B; CF301 Study Investigators: Inhaled dry powder mannitol in cystic fibrosis: An efficacy and safety study. Eur Respir J. 2011;38:1071-1080
9. Mentz WM, Brown JB, Friedman M, Stutts MJ, Gatzy JT, and Boucher RC. Deposition, clearance, and effects of aerosolized amiloride in sheep airways. Am Rev Respir Dis. 1986;134:938-943. (Pubitemid 17171650)
10. Köhler D, App E, Schmitz-Schumann M, Wurtemberger G, and Matthys H: Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl. 1986;146:319-326
11. App EM, King M, Helfesrieder R, Köhler D, and Matthys H: Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis. 1990;141:605-612
12. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, and Boucher RC: A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 1990;322:1189- 1194. (Pubitemid 20137850)
13. Graham A, Hasani A, Alton EW, Martin GP, Marriott C, Hodson ME, Clarke SW, and Geddes DM: No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Resp J. 1993;6:1243-1248. (Pubitemid 23329537)
14. Bowler IM, Kelman B, Worthington D, Littlewood JM, Watson A, Conway SP, Smye SW, James SL, and Sheldon TA: Nebulised amiloride in respiratory exacerbations of cystic fibrosis: A randomised controlled trial. Arch Dis Child. 1995;73:427-430
15. Pons G, Marchand MC, d'Athis P, Sauvage E, Foucard C, Chaumet-Riffaur P, Sautegeau A, Navarro J, and Lenoir G; Amiloride-AFLM Collaborative Study Group: French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol. 2000;30:25-31
16. Donaldson SH, Bennett W, Zeman K, Kairalla AA, Knowles MR, and Boucher RC: A pilot study of amiloride and hypertonic saline in cystic fibrosis [Abstract 325]. Pediatr Pulmonol. 2004;38(.S27):300
17. Burrows E, Southern KW, and Noone P: Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev. 2006;3:CD005087
18. Hirsh AJ, Sabater JR, Zamurs A, Smith RT, Paradiso AM, Hopkins S, Abraham WM, and Boucher RC: Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther. 2004;311:929-938. (Pubitemid 39612697)
19. Thelin W, Hirsh AJ, St George J, and Boucher R: Novel ENaC blockers are potent enhancers of airway hydration [Abstract 294]. Pediatr Pulmonol. 2007;42(.S30):306
20. Donaldson SH, and Boucher RC: Sodium channels and cystic fibrosis. Chest. 2007;132:1631-1636. (Pubitemid 350156022)
21. Hunt T, Atherton-Watson HC, Axford J, Collingwood SP, Coote KJ, Cox B, Czarnecki S, Danahay H, Devereux N, Howsham C, Hunt P, Paddock V, Paisley D, and Young A: Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: Quaternary amines. Bioorg Med Chem Lett. 2011;22:929-932
22. Hirsh AJ, St George J, Thelin W, Stapleton K, Montgomery B, Boucher R, and Johnson MR: GS 9411: A potential aerosol pharmacotherapy for CF [Abstract]. Am J Respir Crit Care Med. 2009;179: A1195
23. Hirsh AJ, St George J, Zamurs A, Boucher RC, and Johnson RM: Combination therapy using a novel epithelial sodium channel blocker and hypertonic saline [Abstract 256]. Pediatr Pulmonol. 2006;41(.S29):296-297
24. Donaldson SH: Hydrator therapies for cystic fibrosis lung disease. Pediatr Pulmonol. 2008;43:S18-S23
25. Singer GG, and Brenner BM: Fluid and electrolyte disturbances. In: E Braunwald, AS Fauci, DL Kasper, SL Hauser, DL Longo, and JL Jameson, (eds). Harrison's Principles of Internal Medicine, 15th ed. McGraw-Hill, New York, NY; pp. 271-283, 2001
26. Soundararajan R, Pearce D, and Ziera T: The role of the ENaC-regulatory complex in aldosterone-mediated sodium transport. Mol Cell Endocrinol. 2012;350:242-247
27. Rodan AR, Cheng CJ, and Huang CL: Recent advances in distal tubular potassium handling. Am J Physiol Renal Physiol. 2011;300:F821-F827
28. Rabinowitz L: Aldosterone and potassium homeostasis. Kidney Int. 1996;49:1738-1742.